Source:http://linkedlifedata.com/resource/pubmed/id/19141699
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2009-2-19
|
| pubmed:abstractText |
We studied the effects of lifetime exposure to dietary soy isoflavones in an azoxymethane (AOM)-induced rat colon cancer model. Male pups born to Sprague-Dawley rats exposed (including during pregnancy and lactation) to soy isoflavones at either no (0 mg = control), low (40 mg), or high (1000 mg) doses/kg diet were weaned and continued receiving their respective parental diets until the end of the study. Weaned rats received 2 subcutaneous injections (15 mg/kg body weight) of AOM 1 wk apart. After 26 wk, rats were killed and the coordinates of colon aberrant crypt foci (ACF) and tumors were determined. Expression of estrogen receptor (ER)-beta was assessed in rat colon tumors and in DLD-1 human colon adenocarcinoma cells exposed to soy isoflavones. Compared with the control, soy isoflavones did not affect incidences or multiplicities of colon ACF or tumors. Low-dose soy isoflavones decreased tumor burden and size compared with the control (P < 0.05). Expression of ERbeta increased in colon tumors of soy isoflavone-treated groups compared with the control. Soy isoflavones dose-dependently arrested the growth of DLD-1 cells and at subcytotoxic levels increased the expression of ERbeta. Our results suggest that pre- and postnatal exposure to dietary soy isoflavones suppresses the growth of colon tumors in male rats. The overexpression of ERbeta in both rat colon tumors and DLD-1 cells caused by soy isoflavones suggests that ERbeta is a critical mediator in mitigating its cancer-preventive effects.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1541-6100
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
139
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
474-81
|
| pubmed:meshHeading |
pubmed-meshheading:19141699-Adenocarcinoma,
pubmed-meshheading:19141699-Animals,
pubmed-meshheading:19141699-Animals, Newborn,
pubmed-meshheading:19141699-Azoxymethane,
pubmed-meshheading:19141699-Carcinogens,
pubmed-meshheading:19141699-Cell Line, Tumor,
pubmed-meshheading:19141699-Colonic Neoplasms,
pubmed-meshheading:19141699-Diet,
pubmed-meshheading:19141699-Estrogen Receptor beta,
pubmed-meshheading:19141699-Female,
pubmed-meshheading:19141699-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:19141699-Humans,
pubmed-meshheading:19141699-Isoflavones,
pubmed-meshheading:19141699-Male,
pubmed-meshheading:19141699-Pregnancy,
pubmed-meshheading:19141699-Prenatal Exposure Delayed Effects,
pubmed-meshheading:19141699-Random Allocation,
pubmed-meshheading:19141699-Rats,
pubmed-meshheading:19141699-Rats, Sprague-Dawley,
pubmed-meshheading:19141699-Soybeans
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Soy isoflavones modulate azoxymethane-induced rat colon carcinogenesis exposed pre- and postnatally and inhibit growth of DLD-1 human colon adenocarcinoma cells by increasing the expression of estrogen receptor-beta.
|
| pubmed:affiliation |
Toxicology Research Division, Bureau of Chemical Safety, Food Directorate, Health Canada, K1A 0L2 Ottawa, Ontario. jayadev_raju@hc-sc.gc.ca
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|